Skip to main content

Advertisement

SpringerLink
Log in

Impact of Neoadjuvant Chemotherapy on Locoregional Surgical Treatment of Breast Cancer

  • Breast Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Preoperative (neoadjuvant) chemotherapy (NC) has become the standard of care for patients with locally advanced breast cancer and is being increasingly used in those with large operable disease. Its main clinical advantages from a surgical therapy standpoint include the potential for conversion of patients requiring mastectomy to breast-conservation candidates, the potential for improving the cosmetic outcome following lumpectomy by decreasing the size of the primary breast tumor even if the patient is a lumpectomy candidate at presentation, and the potential for converting patients who present with positive axillary nodes and who would initially require axillary lymph node dissection to candidates for sentinel lymph node biopsy alone. Important steps are required from the time of diagnosis until the time of surgical resection to ensure successful locoregional therapy outcomes in patients treated with NC. They include accurate assessment of the location and extent of the primary breast tumor and determination of axillary nodal status before and after NC. This information is critical for successful execution of the surgical plan and to optimize the use of adjuvant radiotherapy following NC. In the future, development of more active neoadjuvant chemotherapy regimens and novel molecular and imaging techniques will undoubtedly lead to further individualization of breast cancer surgical management following NC, including the possibility of avoiding surgical resection in cases with a high likelihood of achieving a pathological complete response.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;96–102.

  2. Van der Hage JA, van de Velde CJ, Julien JP, et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer Trial 10902. J Clin Oncol. 2001;19:4224–37.

    PubMed  Google Scholar 

  3. Gianni L, Baselga J, Eirmann W, et al. European Cooperative Trial in Operable Breast Cancer (ECTO): improved freedom from progression (FFP) from adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide methotrexate and fluorouracil (CMF). J Clin Oncol. 2005;23:7s abstract 513.

    Article  Google Scholar 

  4. Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003;21:4165–74.

    Article  CAS  PubMed  Google Scholar 

  5. Gianni L, Baselga J, Eiermann W, et al. First report of the European Cooperative Trial in Operable Breast Cancer (ECTO): effect of primary systemic therapy. Proc Am Soc Clin Oncol. 2002;21:34a abstract 132.

  6. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164–72.

    Article  PubMed  Google Scholar 

  7. El-Tamer M, Axiotis C, Kim E, et al. Accurate prediction of the amount of in situ tumor in palpable breast cancers by core needle biopsy: implications for neoadjuvant therapy. Ann Surg Oncol. 1999;6:461–6.

    Article  CAS  PubMed  Google Scholar 

  8. Kaneko S, Gerasimova T, Butler WM, et al. The use of FISH on breast core needle samples for the presurgical assessment of HER-2 oncogene status. Exp Mol Pathol. 2002;73:61–6.

    Article  CAS  PubMed  Google Scholar 

  9. Taucher S, Rudas M, Gnant M, et al. Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy. Endocr Relat Cancer. 2003;10:91–8.

    Article  CAS  PubMed  Google Scholar 

  10. Kuerer HM, Singletary SE, Buzdar AU, et al. Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma. Am J Surg. 2001;182:601–8.

    Article  CAS  PubMed  Google Scholar 

  11. Esserman L, Hylton N, Yassa L, et al. Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging. J Clin Oncol. 1999;17:110–9.

    CAS  PubMed  Google Scholar 

  12. Stoutjesdijk MJ, Boetes C, Jager GJ, et al. Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst. 2001;93:1095–102.

    Article  CAS  PubMed  Google Scholar 

  13. Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med. 2004;351:427–37.

    Article  CAS  PubMed  Google Scholar 

  14. Esserman L, Kaplan E, Partridge S, et al. MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer. Ann Surg Oncol. 2001;8:549–59.

    Article  CAS  PubMed  Google Scholar 

  15. Nakamura S, Kenjo H, Nishio T, et al. Efficacy of 3D-MR mammography for breast conserving surgery after neoadjuvant chemotherapy. Breast Cancer. 2002;9:15–9.

    Article  PubMed  Google Scholar 

  16. Nakamura S, Kenjo H, Nishio T, et al. 3D-MR mammography-guided breast conserving surgery after neoadjuvant chemotherapy: clinical results and future perspectives with reference to FDG-PET. Breast Cancer. 2001;8:351–4.

    Article  CAS  PubMed  Google Scholar 

  17. Morris EA. Review of breast MRI: indications and limitations. Semin Roentgenol. 2001;36:226–37.

    Article  CAS  PubMed  Google Scholar 

  18. Baron LF, Baron PL, Ackerman SJ, et al. Sonographically guided clip placement facilitates localization of breast cancer after neoadjuvant chemotherapy. AJR Am J Roentgenol. 2000;174:539–40.

    Article  CAS  PubMed  Google Scholar 

  19. Alonso-Bartolome P, Ortega Garcia E, Garijo Ayensa F, et al. Utility of the tumor bed marker in patients with breast cancer receiving induction chemotherapy. Acta Radiol. 2002;43:29–33.

    Article  CAS  PubMed  Google Scholar 

  20. Danforth DN Jr, Aloj L, Carrasquillo JA, et al. The role of 18F-FDG-PET in the local/regional evaluation of women with breast cancer. Breast Cancer Res Treat. 2002;75:135–46.

    Article  CAS  PubMed  Google Scholar 

  21. Mankoff DA, Dunnwald LK, Gralow JR, et al. Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]-sestamibi scintimammography. Cancer. 1999;85:2410–23.

    Article  CAS  PubMed  Google Scholar 

  22. Akashi-Tanaka S, Fukutomi T, Sato N, et al. The role of computed tomography in the selection of breast cancer treatment. Breast Cancer. 2003;10:198–203.

    Article  PubMed  Google Scholar 

  23. Oruwari JU, Chung MA, Koelliker S, et al. Axillary staging using ultrasound-guided fine needle aspiration biopsy in locally advanced breast cancer. Am J Surg. 2002;184:307–9.

    Article  PubMed  Google Scholar 

  24. Krishnamurthy S, Sneige N, Bedi DG, et al. Role of ultrasound-guided fine-needle aspiration of indeterminate and suspicious axillary lymph nodes in the initial staging of breast carcinoma. Cancer. 2002;95:982–8.

    Article  PubMed  Google Scholar 

  25. Bedrosian I, Reynolds C, Mick R, et al. Accuracy of sentinel lymph node biopsy in patients with large primary breast tumors. Cancer. 2000;88:2540–5.

    Article  CAS  PubMed  Google Scholar 

  26. Schrenk P, Hochreiner G, Fridrik M, et al. Sentinel node biopsy performed before preoperative chemotherapy for axillary lymph node staging in breast cancer. Breast J. 2003;9:282–7.

    Article  PubMed  Google Scholar 

  27. Sabel MS, Schott AF, Kleer CG, et al. Sentinel node biopsy prior to neoadjuvant chemotherapy. Am J Surg. 2003;186:102–5.

    Article  PubMed  Google Scholar 

  28. Ollila DW, Neuman HB, Sartor C, et al. Lymphatic mapping and sentinel lymphadenectomy prior to neoadjuvant chemotherapy in patients with large breast cancers. Am J Surg. 2005;190:371–5.

    Article  PubMed  Google Scholar 

  29. Chung MH, Ye W, Giuliano AE. Role for sentinel lymph node dissection in the management of large (> or = 5 cm) invasive breast cancer. Ann Surg Oncol. 2001;8:688–92.

    CAS  PubMed  Google Scholar 

  30. Krag DN, Anderson SJ, Julian TB, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007;8:881–8.

    Article  CAS  PubMed  Google Scholar 

  31. Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349:546–53.

    Article  PubMed  Google Scholar 

  32. Tafra L, Lannin DR, Swanson MS, et al. Multicenter trial of sentinel node biopsy for breast cancer using both technetium sulfur colloid and isosulfan blue dye. Ann Surg. 2001;233:51–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  33. McMasters KM, Tuttle TM, Carlson DJ, et al. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol. 2000;18:2560–6.

    CAS  PubMed  Google Scholar 

  34. Mauriac L, MacGrogan G, Avril A, et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up—Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol. 1999;10:47–52.

    Article  CAS  PubMed  Google Scholar 

  35. Bonadonna G, Valagussa P, Brambilla C, et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol. 1998;16:93–100.

    CAS  PubMed  Google Scholar 

  36. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997;15:2483–93.

    CAS  PubMed  Google Scholar 

  37. Cocquyt VF, Blondeel PN, Depypere HT, et al. Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma. Eur J Surg Oncol. 2003;29:361–7.

    Article  CAS  PubMed  Google Scholar 

  38. Cristofanilli M, Gonzalez-Angulo A, Sneige N, et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol. 2005;23:41–8.

    Article  PubMed  Google Scholar 

  39. Julian TB, Anderson S, Fourchotte V, et al. Is invasive lobular breast cancer a prognostic factor for neoadjuvant chemotherapy response and long term outcomes? Br Cancer Res Treat. 2006;100:S146 abstract 3065.

    Google Scholar 

  40. Sinn HP, Schmid H, Junkermann H, et al. [Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy.] Geburtshilfe Frauenheilkd. 1994;54:552–8.

    Article  CAS  PubMed  Google Scholar 

  41. Newman LA, Buzdar AU, Singletary SE, et al. A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility. Ann Surg Oncol. 2002;9:228–34.

    Article  PubMed  Google Scholar 

  42. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005;97:188–94.

    Article  PubMed  Google Scholar 

  43. Mieog JS, van der Hage JA, van de Velde CJ: Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev. 2007;CD005002.

  44. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13:25–32.

    Article  CAS  PubMed  Google Scholar 

  45. Robidoux A, Tang G, Rastogi P, et al. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol. 2013;4:1183–92.

  46. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 375:377–84.

  47. Breslin TM, Cohen L, Sahin A, et al. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol. 2000;18:3480–6.

    CAS  PubMed  Google Scholar 

  48. Nason KS, Anderson BO, Byrd DR, et al. Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. Cancer. 2000;89:2187–94.

    Article  CAS  PubMed  Google Scholar 

  49. Fernandez A, Cortes M, Benito E, et al. Gamma probe sentinel node localization and biopsy in breast cancer patients treated with a neoadjuvant chemotherapy scheme. Nucl Med Commun. 2001;22:361–6.

    Article  CAS  PubMed  Google Scholar 

  50. Haid A, Tausch C, Lang A, et al. Is sentinel lymph node biopsy reliable and indicated after preoperative chemotherapy in patients with breast carcinoma? Cancer. 2001;92:1080–4.

    Article  CAS  PubMed  Google Scholar 

  51. Stearns V, Ewing CA, Slack R, et al. Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Ann Surg Oncol. 2002;9:235–42.

    Article  PubMed  Google Scholar 

  52. Miller AR, Thomason VE, Yeh IT, et al. Analysis of sentinel lymph node mapping with immediate pathologic review in patients receiving preoperative chemotherapy for breast carcinoma. Ann Surg Oncol. 2002;9:243–7.

    Article  PubMed  Google Scholar 

  53. Brady EW. Sentinel lymph node mapping following neoadjuvant chemotherapy for breast cancer. Breast J. 2002;8:97–100.

    Article  PubMed  Google Scholar 

  54. Reitsamer R, Peintinger F, Rettenbacher L, et al. Sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy. J Surg Oncol. 2003;84:63–7.

    Article  PubMed  Google Scholar 

  55. Schwartz GF, Meltzer AJ. Accuracy of axillary sentinel lymph node biopsy following neoadjuvant (induction) chemotherapy for carcinoma of the breast. Breast J. 2003;9:374–9.

    Article  PubMed  Google Scholar 

  56. Balch GC, Mithani SK, Richards KR, et al. Lymphatic mapping and sentinel lymphadenectomy after preoperative therapy for stage II and III breast cancer. Ann Surg Oncol. 2003;10:616–21.

    Article  PubMed  Google Scholar 

  57. Piato JR, Barros AC, Pincerato KM, et al. Sentinel lymph node biopsy in breast cancer after neoadjuvant chemotherapy: a pilot study. Eur J Surg Oncol. 2003;29:118–20.

    Article  PubMed  Google Scholar 

  58. Vigario A, Sapienza MT, Sampaio AP, et al. Primary chemotherapy effect in sentinel node detection in breast cancer. Clin Nucl Med. 2003;28:553–7.

    Article  PubMed  Google Scholar 

  59. Aihara T, Munakata S, Morino H, et al. Feasibility of sentinel node biopsy for breast cancer after neoadjuvant endocrine therapy: a pilot study. J Surg Oncol. 2004;85:77–81.

    Article  PubMed  Google Scholar 

  60. Kang SH, Kang JH, Choi EA, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy. Breast Cancer. 2004;11:233–41 discussion 264–6.

    Article  PubMed  Google Scholar 

  61. Shimazu K, Tamaki Y, Taguchi T, et al. Sentinel lymph node biopsy using periareolar injection of radiocolloid for patients with neoadjuvant chemotherapy-treated breast carcinoma. Cancer. 2004;100:2555–61.

    Article  PubMed  Google Scholar 

  62. Patel NA, Piper G, Patel JA, et al. Accurate axillary nodal staging can be achieved after neoadjuvant therapy for locally advanced breast cancer. Am Surg. 2004;70:696–9 discussion 699–700.

    CAS  PubMed  Google Scholar 

  63. Lang JE, Esserman LJ, Ewing CA, et al. Accuracy of selective sentinel lymphadenectomy after neoadjuvant chemotherapy: effect of clinical node status at presentation. J Am Coll Surg. 2004;199:856–62.

    Article  PubMed  Google Scholar 

  64. Jones JL, Zabicki K, Christian RL, et al. A comparison of sentinel node biopsy before and after neoadjuvant chemotherapy: timing is important. Am J Surg 2005;190:517–20.

    Article  PubMed  Google Scholar 

  65. O’Hea BJ, Hill AD, El-Shirbiny AM, et al. Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan-Kettering Cancer Center. J Am Coll Surg. 1998;186:423–7.

    Article  PubMed  Google Scholar 

  66. Krag DN, Weaver DL, Alex JC, et al. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol. 1993;2:335–9 discussion 340.

    Article  CAS  PubMed  Google Scholar 

  67. Giuliano AE, Kirgan DM, Guenther JM, et al. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220:391–8 discussion 398–401.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  68. Tanaka Y, Maeda H, Ogawa Y, et al. Sentinel node biopsy in breast cancer patients treated with neoadjuvant chemotherapy. Oncol Rep. 2006;15:927–31.

    PubMed  Google Scholar 

  69. Yu JC, Hsu GC, Hsieh CB, et al. Role of sentinel lymphadenectomy combined with intraoperative ultrasound in the assessment of locally advanced breast cancer after neoadjuvant chemotherapy. Ann Surg Oncol. 2007;14:174–80.

    Article  PubMed  Google Scholar 

  70. Shen J, Gilcrease MZ, Babiera GV, et al. Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases. Cancer. 2007;109:1255–63.

    Article  PubMed  Google Scholar 

  71. Lee S, Kim EY, Kang SH, et al. Sentinel node identification rate, but not accuracy, is significantly decreased after pre-operative chemotherapy in axillary node-positive breast cancer patients. Breast Cancer Res Treat. 2007;102:283–8.

    Article  CAS  PubMed  Google Scholar 

  72. Newman EA, Sabel MS, Nees AV, et al. Sentinel lymph node biopsy performed after neoadjuvant chemotherapy is accurate in patients with documented node-positive breast cancer at presentation. Ann Surg Oncol. 2007;14:2946–52.

    Article  PubMed  Google Scholar 

  73. Kinoshita T. Sentinel lymph node biopsy is feasible for breast cancer patients after neoadjuvant chemotherapy. Breast Cancer. 2007;14:10–5.

    Article  PubMed  Google Scholar 

  74. Yamamoto M, Mehta RS, Baick CH, et al. The predictive value of sentinel lymph node biopsy in locally advanced breast cancer patients who have undergone neoadjuvant chemotherapy. Am Surg. 2007;73:977–80.

    PubMed  Google Scholar 

  75. Gimbergues P, Abrial C, Durando X, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy is accurate in breast cancer patients with a clinically negative axillary nodal status at presentation. Ann Surg Oncol. 2008;15:1316–21.

    Article  CAS  PubMed  Google Scholar 

  76. Hino M, Sano M, Sato N, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy in a patient with operable breast cancer. Surg Today. 2008;38:585–91.

    Article  PubMed  Google Scholar 

  77. Tausch C, Konstantiniuk P, Kugler F, et al. Sentinel lymph node biopsy after preoperative chemotherapy for breast cancer: findings from the Austrian Sentinel Node Study Group. Ann Surg Oncol. 2008;15:3378–83.

    Article  PubMed  Google Scholar 

  78. Medina-Franco H, Salgado-Nesme N, Zeron-Medina-Cuairan J. Sentinel lymph node biopsy after neoadjuvant systemic chemotherapy in patients with breast cancer: a prospective pilot trial. Rev Invest Clin. 2008;60:390–4.

    PubMed  Google Scholar 

  79. Hidar S, Bibi M, Gharbi O, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy in inflammatory breast cancer. Int J Surg. 2009;7:272–5.

    Article  PubMed  Google Scholar 

  80. Papa MZ, Zippel D, Kaufman B, et al. Timing of sentinel lymph node biopsy in patients receiving neoadjuvant chemotherapy for breast cancer. J Surg Oncol. 2008;98:403–6.

    Article  PubMed  Google Scholar 

  81. Hunt KK, Yi M, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg. 2009;250:558–66.

    PubMed  Google Scholar 

  82. Mamounas EP, Brown A, Anderson S, et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2005;23:2694–702.

    Article  PubMed  Google Scholar 

  83. Classe JM, Bordes V, Campion L, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol. 2009;27:726–32.

    Article  PubMed  Google Scholar 

  84. Xing Y, Foy M, Cox DD, et al. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg. 2006;93:539–46.

    Article  CAS  PubMed  Google Scholar 

  85. Kelly AM, Dwamena B, Cronin P, et al. Breast cancer sentinel node identification and classification after neoadjuvant chemotherapy: systematic review and meta analysis. Acad Radiol. 2009;16:551–63.

    Article  PubMed  Google Scholar 

  86. Alvarado R, Yi M, Le-Petross H, et al. The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer. Ann Surg Oncol. 2012;19:3177–84.

    Article  PubMed  Google Scholar 

  87. Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310:1455–61.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  88. Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14:609–18.

    Article  PubMed  Google Scholar 

  89. Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC Study. J Clin Oncol. 2015;33:258–64.

    Article  PubMed  Google Scholar 

  90. Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer: a multicenter validation study. N Engl J Med. 1998;339:941–6.

    Article  CAS  PubMed  Google Scholar 

  91. Mamounas EP, Anderson SJ, Dignam JJ, et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol. 2012;30:3960–6.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Florida Health Cancer Center at Orlando Health, Orlando, FL, USA

    Eleftherios P. Mamounas MD, MPH, FACS

Authors
  1. Eleftherios P. Mamounas MD, MPH, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eleftherios P. Mamounas MD, MPH, FACS.

Additional information

Acknowledgment: This educational review series, “Neoadjuvant Therapy in Breast Cancer” is supported by an educational grant from Genentech, Inc. The Society of Surgical Oncology offers CME/MOC for this educational review series. Visit moc.surgonc.org for additional information.

Annals of Surgical Oncology educational reviews represent the journal’s commitment to the peer review and publication of high quality research necessary to define the safety, toxicity, or effectiveness of potential therapeutic agents compared with conventional alternatives.

This Educational Review Series may include information regarding the use of medications that may be outside the approved labeling for these products. Physicians should consult the current prescribing information for these products. Authors of Annals of Surgical Oncology educational reviews are provided at the time of article solicitation with this statement regarding off-label pharmaceutical information and research.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mamounas, E.P. Impact of Neoadjuvant Chemotherapy on Locoregional Surgical Treatment of Breast Cancer. Ann Surg Oncol 22, 1425–1433 (2015). https://doi.org/10.1245/s10434-015-4406-6

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-015-4406-6

Keywords

Search

Navigation